Barely Significant
← all excerpts

The changing face of acute myeloid leukemia therapeutics in the elderly population.

South Asian J Cancer · 2015 · PMC4382773 · PMID 25839008

Europe PMCDOI
1
hedged sentence
0.1080
closest p · 2.2× alpha
0.1080
boldest claim

The sentences

showed a trendP = 0.108not close (p > 0.1)
Hypomethylating agents are the most frequently used agents in the therapy of elderly AML in the US and Europe.[ 12 ] The DACO-016 study compared the efficacy and safety of decitabine (20 mg/m 2 /day for 5 days every 4-week) versus investigators choice (including LDAC 20 mg/m 2 /day for 10 days every 4-week or best supportive care) in 485 AML patients (median age 73 years) ineligible for cytotoxic chemotherapy.[ 12 , 13 ] The initial analysis showed a trend toward improved survival with decitabine (7.7 vs. 5.0 months; P = 0.108) that became significant ( P = 0.037) with further follow-up.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.